# EDGAR Filing Document

**Accession Number:** 0001043961
**File Stem:** 0001104659-23-038295
**Filing Date:** 2023-3
**Character Count:** 10052
**Document Hash:** 81947f1c0ffffa7c77be4688d959ead7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-038295.hdr.sgml**: 20230329

**ACCESSION NUMBER**: 0001104659-23-038295

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230329

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230329

**DATE AS OF CHANGE**: 20230329

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Precipio, Inc.
- **CENTRAL INDEX KEY:** 0001043961
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 911789357
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36439
- **FILM NUMBER:** 23775107

**BUSINESS ADDRESS:**
- **STREET 1:** 12325 EMMET ST
- **CITY:** OMAHA
- **STATE:** NE
- **ZIP:** 68164
- **BUSINESS PHONE:** 203 787 7888

**MAIL ADDRESS:**
- **STREET 1:** 4 SCIENCE PARK
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06511

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRANSGENOMIC INC
- **DATE OF NAME CHANGE:** 20000119

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

 **WASHINGTON, D. C. 20549**

**FORM 8-K** 

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

Date of report (Date of earliest event reported): March 29, 2023

**PRECIPIO, INC.** *(Exact Name of Registrant as Specified in Its Charter)*

 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36439** | **91-1789357** |
| *(State of Incorporation)* | *(Commission File Number)* | *(I.R.S. Employer Identification No.)* |

---

**4 Science Park, New Haven, CT 06511**

*(Address of principal executive offices) (Zip Code)*

**(203) 787-7888**

*(Registrant's telephone number, including area code)*

**Not Applicable** *(Former name, former address and former fiscal year, if changed since last report date)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Ticker symbol(s) | Name of each exchange on which<br> registered |
| Common Stock, $0.01 par value per share | PRPO | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 7.01 Regulation FD Disclosure**

On March 28, 2023, Precipio, Inc (the "Company") announced that management will host a Q4-2022 and year-end Shareholder Update Call on Monday, April 3rd, 2023 at 5:00 PM EST. A copy of the letter is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

[99.1](tm2310887d1_ex99-1.htm) [Precipio Inc Press Release](tm2310887d1_ex99-1.htm) <br>104 Cover Page Interactive Data File (cover page XBRL tags are embedded within the Inline XBRL document)

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **PRECIPIO, INC.** | **PRECIPIO, INC.** |
| By: | s/ Ilan Danieli |
| Name: | Ilan Danieli |
| Title: | Chief Executive Officer |

---

Date: March 29, 2023

## Exhibit 99.1

**Exhibit 99.1**

![](image_001.jpg)

**Precipio Announces 2022 Fourth Quarter and Year-End<br> Shareholder Update Call**

 

***Conference Call to be held on Monday, April 3<sup>rd</sup>, 2023 at 5:00 PM EST***

**NEW HAVEN, CT, Globenewswire *– (March 28<sup>th</sup>, 2023)*** - Specialty cancer diagnostics company <u>Precipio, Inc. (NASDAQ: PRPO)</u>, will be hosting its Q4-2022 and year end shareholder update call on Monday, April 3<sup>rd</sup> at 5:00 PM ET. The call will include updates on the Company's current core businesses.

The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call. Participants may also pre-register for the conference call at **<u>https://dpregister.com/sreg/10177120/f8d2d6fc60</u>**. For those that pre-register for the shareholder call, the host service will send a calendar invitation and a direct dial-in number for the call to your email used during registration, which will allow for the registrant to bypass the operator.

Listeners interested in submitting questions in advance should email their questions to <u>investors@precipiodx.com</u> and management will do its best to address those questions during the call.

A replay of the call will be available approximately 24 hours after the call and may be accessed via the investors page located on Precipio's website or at <u>http://www.precipiodx.com/investors/</u>

**About Precipio**

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit <u>www.precipiodx.com</u>.

Please follow us on <u>LinkedIn</u>, Twitter <u>@PrecipioDx</u> and on <u>Facebook</u>.

**Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "will," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management's expectations, or could affect the company's ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the company's business, operations and employees and the other factors that are described in the sections entitled "Risk Factors" and "Management's Discussion and Analysis" in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated from time to time in the company's Securities and Exchange Commission filings.

The company's forward-looking statements in this press release are based on management's current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

**Inquiries:**

**<u>investors@precipiodx.com</u>**

+1-203-787-7888 Ext. 523